142
Participants
Start Date
September 30, 2013
Primary Completion Date
September 30, 2014
Study Completion Date
November 30, 2014
MT-1303-Low
MT-1303-Middle
MT-1303-High
Placebo
Research Site, Dupnitsa
Research Site, Pleven
Research Site, Sofia
Research Site, Tallinn
Research Site, Tartu
Research Site, Bavaria
Research Site, Cologne
Research Site, Düsseldorf
Research Site, Essen
Research Site, Gera
Research Site, Hamburg
Research Site, Hanau
Research Site, Hessen
Research Site, Kiel
Research Site, Lübeck
Research Site, Mainz
Research Site, Debrecen
Research Site, NyÃ-regyháza
Research Site, Orosháza
Research Site, Szeged
Research Site, Veszprém
Research Site, Jelgava
Research Site, Madona
Research Site, Riga
Research Site, Ventspils
Research Site, Bialystok
Research Site, Bydgoszcz
Research Site, Gdansk
Research Site, Katowice
Research Site, Lodzkie
Research Site, Malopolska
Research Site, Olsztyn
Research Site, Środa Wielkopolska
Research Site, Warsaw
Research Site, Woj. Wielkopolskie
Research Site, Wroclaw
Research Site, Chelyabinsk
Research Site, Moscow
Research Site, Saint Petersburg
Research Site, Saratovskaya
Research Site, Yaroslavl
Research Site, Dniepropetrovsk
Research Site, Dnipro
Research Site, Donetskaya
Research Site, Kyiv
Research Site, Luhansk
Research Site, Lviv
Research Site, Odesa
Research Site, Simferopol
Research Site, Ternopil
Research Site, Uzhhorod
Research Site, Zaporizhzhya
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
INDUSTRY